Lilly, Hanmi and Haisco sign deals worth up to 43 billion6,000 million for technology transfer and joint research
Eli Lilly signed a licensing deal with Hanmi Pharmaceutical worth 12 billion6,000 million and launched a multi-program research collaboration with Haisco worth up to 30 billion5,000 million. Lilly reported that Retevmo reduced the risk of recurrence or death by 3% in a clinical Phase83 trial.
Eli Lilly6 disclosed two major biopharmaceutical collaborations on 1. The company signed a licensing agreement with Hanmi Pharmaceutical for sonefpeglutide. Sonefpeglutide was described as a candidate treatment for short bowel syndrome.
The agreement with Hanmi Pharmaceutical includes terms worth up to 12 billion 6,000 million, the company said. Lilly explained that the deal includes regulatory approval and milestone payments. The agreement's effective date and payment schedule are determined according to the company's announcement.
Lilly also entered into a multi-program research collaboration with Haisco Pharmaceutical. The company disclosed that the collaboration has a potential value of up to 30 billion 5,000 million. The company said the scope of the collaboration will be set for each research project.
Lilly also announced clinical 3trial results for Retevmo. According to the announcement, among patients with early-stage RET fusion-positive lung cancer, the risk of disease recurrence or death decreased by 83%. The company described the results as positive.
The market reaction was also disclosed. Lilly shares traded down in premarket trading by 2.73%. The company said in a press release that it would provide additional information.
Sources: Benzinga
Bullstory synthesized this report from the linked sources. AI may have assisted the writing process. Check the original reports for factual confirmation.